News

February 3, 2020February 3, 2020

AAV Patients Treated According to Guidelines, With Infection Most Common Side Effect, Polish Study Reports

News

People in Poland with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV) are treated according to existing guidelines, and the most common treatment-associated adverse event is infection, according to a nationwide ... Read more

January 29, 2020January 29, 2020

Non-Specific GPA-AAV Symptoms Misdiagnosed as Pneumonia, Case Study Reports

News

An elderly woman was diagnosed with the granulomatosis with polyangiiti (GPA) subtype of ANCA-associated vasculitis (AAV) after being misdiagnosed with pneumonia, illustrating the challenges in diagnosing this condition, according to ... Read more

January 27, 2020January 27, 2020

AAV Can Cause Muscle Weakness, With Diagnosis Requiring Biopsy, Case Study Reports

News

Muscle weakness may be an under-recognized symptom of antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis (AAV) with diagnosis likely requiring a biopsy of the muscle itself, a case report has found. ... Read more

January 22, 2020January 22, 2020

Study Identifies Risk Factors for Higher Cardiovascular Disease Rates in AAV Patients With GPA and EGPA

News

A family history of cardiovascular disease and higher vasculitis disease activity are risk factors for fatal and non-fatal cardiac disease in patients with anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis, a ... Read more

January 20, 2020January 20, 2020

Kidney Transplant is Safe and Effective to Treat Renal Failure in Children With AAV, Small Study Suggests

News

Kidney transplantation is safe and effective for treating children with ANCA-associated vasculitis (AAV) who develop serious kidney problems as a result of their disease, a long-term study in Japan ... Read more

January 15, 2020January 15, 2020

ChemoCentryx Secures $100M Credit to Support Avacopan’s Approval Applications, Potential Commercial Launch

News

ChemoCentryx has secured a credit facility of up to $100 million from Hercules Capital to support the upcoming costs of its new drug application (NDA) for avacopan, its investigational treatment for ANCA-associated vasculitis ... Read more

January 8, 2020January 8, 2020

Elevated Microparticle Levels in AAV Patients Mark Higher Risk of Blood Clots, Study Suggests

News

People with anti‑neutrophil cytoplasmic antibody (ANCA)‑associated vasculitis (AAV) who have high levels of cellular microparticles in their blood may be at higher risk for venous thromboembolism (VTE), a life-threatening ... Read more

January 6, 2020January 6, 2020

S. aureus Bacterium in Nose Not Linked with AAV Relapses, Study Suggests

News

The presence of the bacterium Staphylococcus aureus was not associated with a higher relapse rate of ANCA-associated vasculitis (AAV), a recent study suggests. These results challenge the idea that ... Read more

December 18, 2019December 18, 2019

‘Favorable Outcomes’ with Treatment Likely for Older Adults with AAV, Study Finds

News

Older adults with ANCA-associated vasculitis (AAV) have an overall good prognosis, with a high long-term survival rate, a recent study suggests. Higher frailty scores and elevated levels of C-reactive ... Read more

December 16, 2019December 16, 2019

Rituxan Superior to Azathioprine in Preventing AAV Relapse, Phase 3 Trial Suggests

News

Maintenance therapy with Rituxan (rituximab) is superior to standard care with azathioprine for preventing disease relapses in patients with ANCA-associated vasculitis (AAV) who had achieved remission, results of a ... Read more

Pin It on Pinterest